Novel therapies for severe dyslipidemia originating from human genetics

Current Opinion in Lipidology

Volumn 27, Issue 2, 2016, Pages 112-124

  Gaudet, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

chylomicronemia; drug development; gene based therapies; human genetics; Keywords biodrugs; pharmacogenetics; rare dyslipidemia; severe hypercholesterolemia

Indexed keywords

ALIPOGENE TIPARVOVEC; ALIROCUMAB; BIOLOGICAL MARKER; BOCOCIZUMAB; EVINACUMAB; EVOLOCUMAB; GEMCABENE; LOMITAPIDE; MIPOMERSEN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VOLANESORSEN; ANTILIPEMIC AGENT;

CARDIOVASCULAR RISK; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DISEASE SEVERITY; DRUG RESPONSE; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC LINKAGE; GENETIC VARIABILITY; GENETICS; HOMOZYGOSITY; HUMAN; HUMAN GENETICS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; MOLECULAR DIAGNOSIS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA TRANSLATION; DYSLIPIDEMIAS; MEDICAL GENETICS; PHARMACOGENETIC VARIANT; TREATMENT OUTCOME;

DYSLIPIDEMIAS; GENETICS, MEDICAL; HUMANS; HYPOLIPIDEMIC AGENTS; PHARMACOGENOMIC VARIANTS; TREATMENT OUTCOME;

EID: 84960330442     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000281     Document Type: Review

References (87)

1. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707-713
2. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40: 161-169
3. Reddy MV, Iatan I, Weissglas-Volkov D, et al. Exome sequencing identifies 2 rare variants for low high-density lipoprotein cholesterol in an extended family. Circ Cardiovasc Genet 2012; 5: 538-546
4. Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Eng J Med 2006; 354: 1264-1272
5. Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365: 65-69
6. Morrison AC, Voorman A, Johnson AD, et al. Whole-genome sequence-based analysis of high-density lipoprotein cholesterol. Nat Genet 2013; 45: 899-901
7. Barylski M, Toth PP, Nikolic D, et al. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 2014; 28: 453-461
8. Tardif JC, Rhe aume E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015; 8: 372-382
9. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921
10. Schuster SC. Next-generation sequencing transforms today s biology. Nat Methods 2008; 5: 16-18
11. Khetarpal SA, Rader DJ. Genetics of lipid traits: Genome-wide approaches yield new biology and clues to causality in coronary artery disease. Biochim Biophys Acta 2014; 1842: 2010-2020
12. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45: 1345-1352
13. Clee SM, Loubser O, Collins J, et al. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clin Genet 2001; 60: 293-300
14. Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013; 20: 36136-36139
15. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363: 2220-2227
16. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res 2015; 56: 1308-1317
17. http: //www.ionispharma.com/pipeline/. [Accessed January 2016].
18. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008; 322: 1702-1705
19. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Crosby J, PelosoGM, Auer PL, et al. Loss-offunction mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371: 22-31
20. Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med 2015; 373: 438-447
21. http: //www.alnylam.com/product-pipeline/. [Accessed January 2016].
22. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156
23. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-1509
24. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-1499
25. Ballantyne CM, Neutel J, Cropp A, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol 2015; 115: 1212-1221
26. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet 2014; 383: 60-68
27. Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 2014; 115: 488-492
28. Galabova G, Brunner S, Winsauer G, et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One 2014; 9: e114469
29. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Nat Acad Sci 1987; 84: 6919-6923
30. Skogsberg J, McMahon AD, Karpe F, et al. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 2003; 254: 597-604
31. Panta R, Dahal K, Kunwar S. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials. J Clin Lipidol 2015; 9: 217-225
32. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014; 13: 622-638
33. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381: 40-46
34. Bays HE, Schwartz S. Littlejohn T 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 2011; 96: 2889-2897
35. Fojo SS, Lohse P, Parrott C, et al. A nonsense mutation in the apolipoprotein C-II Padova gene in a patient with apolipoprotein C-II deficiency. J Clin Invest 1989; 84: 1215-1219
36. Amar MJ, Sakurai T, Sakurai-Ikuta A, et al. A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther 2015; 352: 227-235
37. Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22: 336-345
38. Pisciotta L, Vitali C, Favari E, et al. A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoAIGuastalla). J Clin Lipidol 2015; 9: 837-846
39. Gualandri V, Franceschini G, Sirtori CR, et al. AI(Milano) apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985; 37: 1083-1097
40. Gotoda T, Yamada N, Murase T, et al. Differential phenotypic expression by three mutant alleles in familial lecithin: cholesterol acyltransferase deficiency. Lancet 1991; 338: 778-781
41. Tardy C, Goffinet M, Boubekeur N, et al. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 2014; 232: 110-118
42. Shamburek RD, Bakker-Arkema R, Shamburek AM, et al. Safety and tolerability of ACP-501, a recombinant human lecithin: cholesterol acyltransferase, in a phase 1 single-dose escalation study. Circ Res 2016; 118: 73-82
43. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518-2528
44. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368: 503-512
45. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386: 1472-1483
46. Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33: 2909-2914
47. Burton BK, Balwani M, Feillet F, et al. A Phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 2015; 373: 1010-1020
48. Somanathan S, Jacobs F, Wang Q, et al. AAV vectors expressing LDLR gainof-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. Circ Res 2014; 115: 591-599
49. Bisgaier CL, Auerbach BJ. Gemcabene and atorvastatin alone and combined markedly reduce LDL-C in LDL receptor-deficient mice, a model of homozygous familial hypercholesterolemia. Circulation 2015; 132: A17824
50. Sviridov D, Remaley AT. High-density lipoprotein mimetics: promises and challenges. Biochem J 2015; 472: 249-259
51. Raabe M, Veniant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 1999; 103: 1287-1298
52. Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 2014; 25: 387-393
53. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003; 100: 928-933
54. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2015; 36: 539-550
55. Brahm AJ, Hegele RA. Chylomicronaemia: current diagnosis and future therapies. Nat Rev Endocrinol 2015; 11: 352-362
56. Feng Q, Baker SS, Liu W, et al. Increased apolipoprotein A5 expression in human and rat nonalcoholic fatty livers. Pathology 2015; 47: 341-348
57. Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518: 102-106
58. Gaudet D, Méthot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012; 23: 310-320
59. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013; 19: 889-891
60. Ferreira V, Twisk J, Kwikkers K, et al. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. Hum Gene Ther 2014; 25: 180-188
61. Melchiorri D, Pani L, Gasparini P, Cossu G, et al. Regulatory evaluation of Glybera in Europe - two committees, one mission. Nat Rev Drug Discov 2013; 12: 719
62. Ooi EM, Barrett PH, Chan DC, et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008; 114: 611-624
63. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014; 371: 2200-2206
64. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev 2015; 36: 131-147
65. Bell DA, Watts GF. Contemporary and novel therapeutic options for hypertriglyceridemia. Clin Ther 2015; 37: 2732-2750
66. Meyers CD, Tremblay K, Amer A, et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis 2015; 14: 8
67. Kassner U, Schlabs T, Rosada A, et al. Lipoprotein(a): An independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler Suppl 2015; 18: 263-267
68. Kingwell BA, Chapman MJ, Kontush A2, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov 2014; 13: 445-464
69. Dunnigan MG, Cochrane MA, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med 1974; 43: 33-48
70. Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol 2015; 35: 689-699
71. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1, 300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63: 1278-1288
72. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014; 114: 711-715
73. Hovingh GK, Smits LP, Stefanutti C, et al. The effect of an apolipoprotein A-Icontaining high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. Am Heart J 2015; 169: 736-742
74. Glukhova A, Hinkovska-Galcheva V, Kelly R, et al. Structure and function of lysosomal phospholipase A2 and lecithin: cholesterol acyltransferase. Nat Commun 2015; 6: 6250
75. Reiner Z, Guardamagna O, Nair D, et al. Lysosomal acid lipase deficiency-an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014; 235: 21-30
76. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005; 102: 8132-8137
77. Salen G, von Bergmann K, Lütjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004; 109: 966-971
78. Gil-Zamorano J, Martin R, Daimiel L, et al. Docosahexaenoic acid modulates the enterocyte Caco-2 cell expression of microRNAs involved in lipid metabolism J Nutr 2014; 144: 575-585
79. Wagschal A, Najafi-Shoushtari SH, Wang L, et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med 2015; 21: 1290-1297
80. Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPL S447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012; 97: 1635-1644
81. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742
82. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351-361
83. Kathiresan S. Developing medicines that mimic the natural successes of the & Kathiresan S. Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J Am Coll Cardiol 2015; 65: 1562-1566
84. Rosenson RS, Davidson MH, Hirsh BJ, et al. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol 2014; 64: 2525-2540
85. Schaeffer L, Gohlke H, Muller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006; 15: 1745-1756
86. Berglund L, Wiklund O, Eggertsen G, et al. Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy. J Intern Med 1993; 233: 173-178
87. Brisson D, Ledoux K, BosséY, et al. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. Pharmacogenetics 2002; 12: 313-320